BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
See today's BioWorld
Home
» Aventis Pasteur Files For Approval Of Long-Acting Meningitis Vaccine
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Aventis Pasteur Files For Approval Of Long-Acting Meningitis Vaccine
Dec. 29, 2003
By
Kim Coghill
No Comments
Aventis Pasteur filed a biologics license application for Menactra, a conjugate vaccine believed to provide protection against meningococcal meningitis for a longer period than the company's currently marketed product. (BioWorld Today)
BioWorld